Ionis Pharmaceuticals Inc [IONS] stock prices are up 1.29% to $34.47 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IONS shares have gain 5.96% over the last week, with a monthly amount glided 20.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on April 07, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $45. Previously, Redburn Atlantic started tracking the stock with Neutral rating on March 31, 2025, and set its price target to $39. On August 02, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $60 on the stock. Leerink Partners upgraded its rating to a Outperform and increased its price target to $62 on July 24, 2024. Bernstein upgraded its rating to Mkt Perform for this stock on June 14, 2024, but kept the price target unchanged to $44. In a note dated April 10, 2024, Wolfe Research upgraded an Outperform rating on this stock but restated the target price of $58.
The stock price of Ionis Pharmaceuticals Inc [IONS] has been fluctuating between $23.95 and $52.34 over the past year. Currently, Wall Street analysts expect the stock to reach $51.68 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $34.47 at the most recent close of the market. An investor can expect a potential return of 49.93% based on the average IONS price forecast.
Analyzing the IONS fundamentals
The Ionis Pharmaceuticals Inc [NASDAQ:IONS] reported sales of 717.68M for trailing twelve months, representing a surge of 10.14%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -1.11%, Pretax Profit Margin comes in at -1.11%, and Net Profit Margin reading is -0.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.0 and Total Capital is -0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.96.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Ionis Pharmaceuticals Inc [NASDAQ:IONS]’s Current Ratio is 9.66. As well, the Quick Ratio is 9.62, while the Cash Ratio is 1.06. Considering the valuation of this stock, the price to sales ratio is 7.64, the price to book ratio is 11.52.
Transactions by insiders
Recent insider trading involved Hayden Michael R, Director, that happened on May 01 ’25 when 15000.0 shares were purchased. EVP, Corp and Development Ops, Birchler Brian completed a deal on Apr 16 ’25 to sell 680.0 shares. Meanwhile, EVP, Chf GL Pdt Str Ofcr Jenne Kyle sold 3016.0 shares on Apr 16 ’25.
